Subjects who received cediranib, a pan-VEGF-receptor tyrosine kinase inhibitor, showed a vessel structure more similar to the tumor-free brain tissues without indication of further angiogenesis, when compared to the subgroup who did not receive anti-angiogenic therapy (di Tomaso et al., 2011). Here, VEGFA is linked to neoplasm.